A Study of PD-0332991 + Letrozole vs. Letrozole for 1st Line Treatment of Postmenopausal Women with ER+/HER2- Advanced Breast Cancer (ClinicalTrials.gov NCT017240427). Here, ESR1 is linked to breast carcinoma.